Pfizer and Athersys drew up a US$6 M global pact to develop and commercialise Multistem® for the treatment of inflammatory bowel disease (IBD). Athersys has developed MultiStem a patented and proprietary “off the shelf” stem cell therapy with potential utility in multiple disease indications.